Welcome to our dedicated page for Scilex Holding Company news (Ticker: SCLXW), a resource for investors and traders seeking the latest updates and insights on Scilex Holding Company stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Scilex Holding Company's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Scilex Holding Company's position in the market.
Scilex Holding Company (Nasdaq: SCLX) announced a worldwide exclusive license, with sublicense rights, to Datavault AI’s AI-driven technology to build a Biotech Exchange for tokenizing, trading and monetizing biotech assets including genomic, DNA, diagnostic, therapeutic and drug data.
The agreement includes a non-refundable upfront license fee payable in four equal installments of $2.5 million (totaling $10.0 million) due by September 30, 2026 and contingent sales milestone payments of up to $2.55 billion. The license covers a portfolio of issued and pending patents, including key pending U.S. application 17/941,623 for tokenizing DNA data.
Scilex Holding Company (Nasdaq: SCLX) announced it will sponsor Dream Bowl 2026 and set a record date of November 14, 2025 for shareholders to receive a Dream Bowl 2026 meme coin distributed by DataVault AI. Shareholders of record on November 14, 2025 will receive one meme coin per common share. Handcrafted digital coins will be airdropped to Data Vault wallets on or after November 25, 2025. The Dream Bowl event is scheduled for January 11, 2026 at AT&T Stadium in Dallas, with additional drone racing and e-sports championships included.
Scilex Holding Company (Nasdaq: SCLX), a non-opioid pain management company, has completed the first tranche of its warrant repurchase agreement with Oramed Pharmaceuticals. The company has repurchased 3,130,000 warrants at $0.01 exercise price for $13 million.
Under the previously disclosed option agreement, Scilex has the right to repurchase a total of 6,500,000 warrants in two tranches for a total of $27 million. The company retains the option to repurchase the remaining 3,370,000 warrants for $14 million before December 31, 2025.
Scilex Holding Company (Nasdaq: SCLX), a revenue-generating company focused on non-opioid pain management and disease treatments, has completed the initial tranche of its $150 million Bitcoin investment in Datavault AI Inc. (Nasdaq: DVLT).
As part of this transaction, Scilex received 15 million shares of Datavault common stock at an effective price of $0.5378 per share. The remaining shares, totaling up to 278,914,094 shares, will be issued in a second tranche as a pre-funded warrant, pending Datavault stockholder approval for issuances exceeding 19.99% of pre-financing shares.
Scilex Holding Company (Nasdaq: SCLX) has announced a strategic $150 million Bitcoin investment in Datavault AI Inc. (Nasdaq: DVLT). The investment will provide Datavault with growth capital to enhance its supercomputing infrastructure and expand data exchanges.
Under the agreement, Scilex will receive up to 278,914,094 shares of Datavault common stock at an effective price of $0.5378 per share. The transaction will occur in two tranches, with 15 million shares issued at initial closing and the remainder through a pre-funded warrant pending stockholder approval.
The partnership aims to capitalize on the growing biotech data monetization market, projected to reach $30-50 billion by 2024. Scilex will gain board representation rights, with the ability to nominate two directors while maintaining 10% ownership or one director at 5-10% ownership.
Scilex Holding Company (Nasdaq: SCLX), a company focused on non-opioid pain management products, has completed a significant non-dilutive transaction with an institutional investor. The company exchanged $200 million worth of Semnur Pharmaceuticals common stock (12.5 million shares at $16.00 per share) for $200 million in Bitcoin (BTC).
The transaction involves Scilex's majority-owned subsidiary Semnur Pharmaceuticals (OTC: SMNR, SMNRW), and the Bitcoin has been received in Scilex's cryptocurrency account. This represents a strategic move by Scilex to convert its equity holdings into digital assets while maintaining its focus on developing treatments for acute and chronic pain, neurodegenerative and cardiometabolic diseases.
Scilex Holding Company (Nasdaq: SCLX), a non-opioid pain management company, has entered into a non-binding, non-exclusive Memorandum of Understanding (MOU) with Biconomy.com for cryptocurrency and treasury management strategies.
The collaboration focuses on three key areas: (1) utilizing Biconomy's cryptocurrency exchange platform for trading Scilex's digital assets, potentially exceeding $1 billion per cryptocurrency, (2) developing a cryptocurrency treasury management strategy balancing security, liquidity, compliance, and yield, and (3) implementing Biconomy's technology to monetize Scilex's digital assets.
Scilex Holding Company (Nasdaq: SCLX) has announced a significant strategic transaction involving the exchange of its Semnur Pharmaceuticals stock holdings for cryptocurrency. The company has signed a Securities Purchase Agreement to exchange $200 million worth of Semnur Pharmaceuticals common stock (12.5 million shares at $16.00 per share) for $200 million in Bitcoin.
The transaction, expected to close on September 23, 2025, is being conducted as a private offering under Section 4(a)(2) of the Securities Act. Additionally, Scilex has partnered with Biconomy.com to assist with crypto currency strategies, including reserve building and treasury management. JW Capital Securities Limited is serving as the financial advisor for this transaction.
Semnur Pharmaceuticals (OTC: SMNR), a majority-owned subsidiary of Scilex Holding Company (Nasdaq: SCLX), has completed its previously announced business combination with Denali Capital Acquisition Corp. Following the merger, Scilex and its affiliates maintain approximately 87.5% ownership of Semnur's common stock.
The combined entity will continue operating as Semnur Pharmaceuticals, with its shares and warrants trading on the OTC Markets under symbols SMNR and SMNRW. The company focuses on developing non-opioid pain management therapeutics, with its lead candidate SP-102 currently in Phase 3 clinical development for chronic radicular pain/sciatica treatment.
Semnur Pharmaceuticals, a majority-owned subsidiary of Scilex Holding Company (Nasdaq: SCLX), announced that shareholders of Denali Capital Acquisition Corp have approved their previously announced business combination at an Extraordinary General Meeting held on September 3, 2025.
The combined entity will operate as Semnur Pharmaceuticals, Inc. The merger is expected to close in September 2025, subject to customary closing conditions. The business combination approval follows Denali's filing of a definitive proxy statement/prospectus with the SEC on August 13, 2025.
Scilex Holding Company is a revenue-generating company focused on non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic disease treatments.
FAQ
What is the current stock price of Scilex Holding Company (SCLXW)?
